The LDL to HDL cholesterol ratio as a valuable tool to evaluate coronary heart disease risk

被引:176
作者
Fernandez, Maria Luz [1 ]
Webb, Densie [2 ]
机构
[1] Univ Connecticut, Dept Nutrit Sci, Storrs, CT 06269 USA
[2] Hlth & Nutr Commun, Austin, TX USA
关键词
LDL cholesterol; HDL cholesterol LDL-C/HDL-C ratio; cardiovascular disease risk; apolipoprotein B; apolipoprotein A-I;
D O I
10.1080/07315724.2008.10719668
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
The current National Cholesterol Education Program Adult Treatment Panel III guidelines recommend specific target levels of LDL cholesterol (LDL-C) and HDL cholesterol (HDL-C) for determining cardiovascular disease (CVD) risk and evaluating the effectiveness of lipid-lowering therapies. While there is a growing consensus that levels of apolipoprotein (apo) B and the ratio of apo B/apo A-I are more accurate predictors of CVD risk, the question has been raised as to whether it is realistic to expect patients and health professionals to switch from cholesterol-based guidelines to apolipoprotein-based guidelines. Because it will take time before apolipoprotein terminology is recognized by the general public and recommended by the NCEP Adult Treatment panel to evaluate risk, it may be more efficacious to continue adhering to the already familiar and proven measurements of the LDL-C/HDL-C ratio. The following review provides evidence that the LDL-C/HDL-C ratio continues to be a valuable and standard tool to evaluate CVD risk in all populations.
引用
收藏
页码:1 / 5
页数:5
相关论文
共 35 条
  • [1] Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease
    Aguilar, David
    Fisher, Marian R.
    O'Connor, Christopher M.
    Dunne, Michael W.
    Muhlestein, Joseph B.
    Yao, Louis
    Gupta, Sandeep
    Benner, Rebecca J.
    Cook, Thomas D.
    Edwards, Dearborn
    Pfeffer, Marc A.
    [J]. AMERICAN HEART JOURNAL, 2006, 152 (02) : 298 - 304
  • [2] AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917
  • [3] Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel
    Barter, PJ
    Ballantyne, CM
    Carmena, R
    Cabezas, MC
    Chapman, MJ
    Couture, P
    De Graaf, J
    Durrington, PN
    Faergeman, O
    Frohlich, J
    Furberg, CD
    Gagne, C
    Haffner, SM
    Humphries, SE
    Jungner, I
    Krauss, RM
    Kwiterovich, P
    Marcovina, S
    Packard, CJ
    Pearson, TA
    Reddy, KS
    Rosenson, R
    Sarrafzadegan, N
    Sniderman, AD
    Stalenhoef, AF
    Stein, E
    Talmud, PJ
    Tonkin, AM
    Walldius, G
    Williams, KMS
    [J]. JOURNAL OF INTERNAL MEDICINE, 2006, 259 (03) : 247 - 258
  • [4] C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes - The Strong Heart Study
    Best, LG
    Zhang, Y
    Lee, ET
    Yeh, JL
    Cowan, L
    Palmieri, V
    Roman, M
    Devereux, RB
    Fabsitz, RR
    Tracy, RP
    Robbins, D
    Davidson, M
    Ahmed, A
    Howard, BV
    [J]. CIRCULATION, 2005, 112 (09) : 1289 - 1295
  • [5] *BLU CROSS BLU SHI, 2005, AP B TEST DIAGN MAN
  • [6] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [7] Cullen P, 1997, CIRCULATION, V96, P2128
  • [8] C-reactive protein and cardiovascular disease: a review of risk prediction and interventions
    de Ferranti, S
    Rifai, N
    [J]. CLINICA CHIMICA ACTA, 2002, 317 (1-2) : 1 - 15
  • [9] Weighing in before the fight - Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy
    Denke, MA
    [J]. CIRCULATION, 2005, 112 (22) : 3368 - 3370
  • [10] Introduction: Apolipoproteins and guidelines for prevention of cardiovascular disease
    Faergeman, O
    [J]. JOURNAL OF INTERNAL MEDICINE, 2006, 259 (05) : 434 - 436